Longevity Services & Practice Library
Every article, presentation, spotlight, and news item we've tagged to Longevity Services & Practice.
Showing 169–192 of 235
Your immune system now has a digital twin for longevity
A digital twin technology modeling immune system dynamics in real time enables predictive health outcomes rather than reactive assessment. This shift from static testing to continuous simulation represents a substantive advance in personalized longevity medicine.
Aging research priorities reshape translational longevity science
The GIMM Festival convened international researchers, clinicians, and stakeholders to identify priority research questions that should guide the aging and longevity field forward. The consensus-driven approach produced a shared roadmap addressing scientific gaps, clinical translation, and societal implications of aging research.
Healthspan Replaces Lifespan in Insurance Risk Models
Insurance industry faces structural pressure to shift from mortality-focused actuarial models toward healthspan optimization as prevention, morbidity reduction, and health data reshape risk assessment. Insurers capable of actively shaping healthy aging outcomes—rather than passively financing disease burden—will gain competitive advantage in an aging demographic landscape.
Insilico forms longevity board to oversee AI aging research
Insilico Medicine established an oversight board combining pharmaceutical expertise with longevity science to accelerate AI-driven drug discovery targeting aging hallmarks. The initiative aims to translate experimental compounds into validated therapeutics across fibrosis, oncology, immunology, and metabolic disease.
Allosteric Bioscience targets longevity research using AI and quantum computing
Allosteric Bioscience is using AI and quantum computing to model molecular mechanisms of aging, targeting pathways including Lamin A, tryptophan metabolism, DNA repair, and mitochondrial function. The approach aims to identify modulators that could reduce age-related disease and extend lifespan.
Insilico forms industry’s first AI Longevity Board
Insilico Medicine has established an industry-focused Longevity Board to guide AI-driven drug development targeting aging itself rather than individual diseases. The board represents a shift from academic longevity research toward pharmaceutical scalability, with leadership from both the biotech sector and major pharmaceutical companies.
Abu Dhabi’s “Future Health” initiative targets longevity, predictive care
Abu Dhabi is establishing a large-scale health infrastructure combining genomic, phenotypic, and wearable data with AI to enable predictive care and accelerate drug discovery. This represents a shift toward population-level early detection and prevention rather than reactive treatment models.
AI app puts longevity data in your pocket
Human Longevity has launched a mobile application that consolidates clinical data, biomarkers, genetic information, and imaging results into a continuous health record accessible to users. The platform uses AI to identify patterns across longitudinal data, shifting preventive health assessment from episodic annual checkups to real-time risk monitoring and interpretation.
Function acquires Getlabs to scale at-home testing
Function's acquisition of Getlabs removes logistical friction from routine health testing by bringing blood draws directly to patients' homes and offices. This operational change addresses a fundamental barrier to consistent health monitoring—the primary prerequisite for sustained, data-driven health optimization.
Executive Health program condenses three months of testing into six hours
Biograph's Executive Physical consolidates comprehensive cardiovascular, metabolic, cancer, and neurological screening into a single six-hour appointment using whole-body MRI, advanced CT, and biomarker analysis. This integrated approach identifies significant health findings in approximately 17 percent of participants and demonstrates measurable metabolic improvements in follow-up assessments.
Klotho Therapy Gains Direct Researcher-Patient Dialogue Model
GARM Clinic convened three leading Klotho researchers with 22 participants receiving a Klotho-based intervention, creating direct dialogue between scientists and patients—a rare model in longevity medicine that reflects shifting expectations for transparency and engagement in therapeutic development.
Global rallies call for aging to be treated
Coordinated global demonstrations are pressuring governments to fund geroscience research and establish regulatory pathways that recognize aging as a treatable medical condition. The rallies highlight a critical gap between accelerating scientific advances in longevity research and stalled policy frameworks that remain anchored to disease-specific treatment models.
Ageist Language Reduces Health Compliance and Longevity
Research over the past decade reveals ageism embedded in language patterns across healthcare, media, and social contexts—a finding that directly shapes how patients interpret health messaging and comply with medical guidance. The way aging is linguistically framed influences both psychological resilience and health behavior, making communication precision a measurable longevity factor.
L-Nutra named Innovator Partner for the Longevity Show 2026
L-Nutra's fasting-mimicking technology platform, validated across 47 clinical trials and 18 university research centers, repositions precision nutrition as essential healthcare infrastructure rather than lifestyle optimization. The company's approach uses targeted nutrient formulations to trigger cellular repair mechanisms—autophagy and metabolic signaling—without the physiological stress of extended fasting, addressing metabolic dysfunction and age-related chronic disease at a systems level.
Body Composition Tracking Outperforms Weight in Longevity Assessment
Restore Hyper Wellness is offering free InBody body composition scans and wellness consultations through August as part of a National Wellness Month campaign. The company references a six-month peer-reviewed study showing that weight changes in participants derived primarily from fat loss while preserving lean muscle mass, underscoring the clinical value of tracking composition rather than scale weight alone.
Home Blood Sampling Unlocks Protein Analysis at Scale
Alamar Biosciences has developed a dried blood spot extraction kit enabling high-sensitivity protein analysis from fingerstick samples collected at home, potentially accelerating large-scale longevity research by reducing barriers to frequent, consistent biosampling across diverse populations.
Life Bio’s Trial: Is the FDA Warming to Rejuvenation?
Life Biosciences' ER-100, a cellular reprogramming therapy, has received FDA clearance for human trials targeting optic nerve disorders. The trial represents a regulatory shift toward rejuvenation-based approaches, potentially positioning cellular age-reversal technologies within mainstream clinical frameworks rather than relegating aging to inevitability.
Biological age and immunosenescence in Colombian centenarians
Colombian centenarians show delayed immunosenescence and younger biological age despite chronological longevity, suggesting that immune system resilience rather than mere longevity is the critical predictor of healthspan. This finding reframes centenarian research toward understanding which mechanisms preserve immune function across decades.
Modifiable risk factors attenuated longevity genetic predisposition on life expectancy in the oldest old
In adults over 80, genetic predisposition for longevity loses predictive power when modifiable risk factors—smoking, physical inactivity, poor diet, excessive alcohol use—remain unaddressed. This demonstrates that behavioral interventions can substantially offset inherited longevity advantages in the oldest-old population.
WHOOP moves into clinical care as Fitbit rebrands to Google Health
Wearable platforms are transitioning from passive data collection to clinical integration, with WHOOP launching telehealth services that connect continuous biometric monitoring to medical records and clinical interpretation. This shift addresses a fundamental gap in current health monitoring: the ability to contextualize patterns within a broader clinical picture and detect meaningful health changes before they become acute problems.
Protein Aggregates Targeted in First Human Longevity Trial
Retro Biosciences, valued at $1.8 billion, has advanced an oral therapeutic into human trials that targets protein aggregate clearance—a mechanism implicated in Alzheimer's pathology. Early safety data show no dose-limiting toxicities, positioning the company to release efficacy findings in 2026 and marking a critical inflection from bench research to clinical validation in longevity therapeutics.
Ultrasound Body Scanning Shifts From Clinic to Wellness Spa
Midjourney is developing whole-body scanning technology integrated into wellness spa environments, positioning routine body composition mapping as an accessible alternative to hospital-based imaging. The approach reflects a fundamental shift in how longevity-focused health systems are designed—moving from intervention-triggered testing to continuous, low-friction monitoring.
SEMCAP expands into beauty’s longevity opportunity
SEMCAP's expansion into beauty and wellness investment signals a structural shift in longevity markets: evidence-backed skincare, haircare, and personalized health products are becoming primary entry points for consumer engagement with aging well, driven by daily rituals and observable body signals rather than clinical diagnostics alone.
Lancôme ties up with Timeline to target skin’s biological age
Lancôme and Timeline have partnered to develop a skincare line using urolithin A (Mitopure), a molecule that enhances mitochondrial function in skin cells to address aging at the cellular level rather than merely treating visible signs. This represents a shift in luxury skincare from cosmetic coverage to supporting long-term cellular vitality and resilience.